BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Lencioni R, Cioni D. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepat Oncol 2016;3:193-200. [PMID: 30191041 DOI: 10.2217/hep-2016-0005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
2 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
3 Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Mol Biol Rep 2017;44:149-58. [PMID: 27981445 DOI: 10.1007/s11033-016-4092-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, Nam TK, Seong J. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014;90:1051-1060. [PMID: 25303890 DOI: 10.1016/j.ijrobp.2014.08.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
5 Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 2016;16:834. [PMID: 27809890 DOI: 10.1186/s12885-016-2894-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
6 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon’s view on latest findings and future perspectives. World J Hepatol. 2015;7:1168-1183. [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
7 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 21.2] [Reference Citation Analysis]
8 Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Huo TL, Liu PH, Hidalgo E, Compagnon P, Lim C, Azoulay D. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. J Hepatol. 2017;67:991-998. [PMID: 28690176 DOI: 10.1016/j.jhep.2017.06.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
9 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7:1913-1920. [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
10 Li GX, Ding ZY, Wang YW, Liu TT, Chen WX, Wu JJ, Xu WQ, Zhu P, Zhang BX. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. J Cell Physiol. 2019;234:11942-11950. [PMID: 30536816 DOI: 10.1002/jcp.27882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
11 Lin ZY, Wu CC, Chuang YH, Chuang WL. Clinical utility of a simple primary culture method in hepatocellular carcinoma patients. J Gastroenterol Hepatol 2015;30:352-7. [PMID: 25087586 DOI: 10.1111/jgh.12693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK, Kuznetsov VA. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol 2018;12:89-113. [PMID: 29117471 DOI: 10.1002/1878-0261.12153] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
13 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
15 Xu Y, Chen J, Wang H, Zheng H, Feng D, Zhang A, Leng J, Duan W, Yang Z, Chen M, Shi X, Cai S, Ji W, Jiang K, Zhang W, Chen Y, Gu W, Dong J, Lu S. Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. Trials 2016;17:492. [PMID: 27724929 DOI: 10.1186/s13063-016-1621-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
16 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016;8:607-15. [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
17 Akamatsu N, Cillo U, Cucchetti A, Donadon M, Pinna AD, Torzilli G, Kokudo N. Surgery and Hepatocellular Carcinoma. Liver Cancer 2016;6:44-50. [PMID: 27995087 DOI: 10.1159/000449344] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
18 An Y, Gao S, Zhao WC, Qiu BA, Xia NX, Zhang PJ, Fan ZP. Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma. World J Gastroenterol 2018;24:2733-40. [PMID: 29991878 DOI: 10.3748/wjg.v24.i25.2733] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
19 Chen CL, Kabiling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol. 2013;10:746-751. [PMID: 24100300 DOI: 10.1038/nrgastro.2013.194] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
20 Hsu C, Po-Ching-Liang S, Hu FC, Cheng AL. Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. Liver Cancer. 2012;1:168-176. [PMID: 24159581 DOI: 10.1159/000343830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, Su RG, Liang TB. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1429-1440. [PMID: 24770582 DOI: 10.1007/s00432-014-1684-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
22 Liu M, Lin M, Lu M, Xu Z, Zheng K, Wang W, Kuang M, Zhuang W, Xie X. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST. Eur Radiol 2015;25:2502-11. [DOI: 10.1007/s00330-015-3611-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
23 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
24 Zhou DY, Qin J, Huang J, Wang F, Xu GP, Lv YT, Zhang JB, Shen LM. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncol Lett 2017;14:4078-84. [PMID: 28943915 DOI: 10.3892/ol.2017.6717] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen J, Ma L, Peng NF, Wang SJ, Li LQ. A meta-analysis of the relationship between glutathione S-transferases gene polymorphism and hepatocellular carcinoma in Asian population. Mol Biol Rep. 2012;39:10383-10393. [PMID: 23053942 DOI: 10.1007/s11033-012-1917-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7:e49717. [PMID: 23284624 DOI: 10.1371/journal.pone.0049717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
27 Adhoute X, Penaranda G, Raoul J, Bourlière M. Nomogram of the Barcelona Clinic Liver Cancer System: external validation in European patients. Liver Int 2016;36:1716-7. [DOI: 10.1111/liv.13171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Luo X, Li Y, Shang Q, Liu H, Song L. Role of Diffusional Kurtosis Imaging in Evaluating the Efficacy of Transcatheter Arterial Chemoembolization in Patients with Liver Cancer. Cancer Biother Radiopharm 2019;34:614-20. [PMID: 31560562 DOI: 10.1089/cbr.2019.2878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kim BK, Kim KA, An C, Yoo EJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Kim MJ. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int 2015;35:1722-30. [PMID: 25444138 DOI: 10.1111/liv.12751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
30 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
31 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60. [PMID: 23566041 DOI: 10.1186/1471-230x-13-60] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
32 Shi C, Zhang Y, Yang H, Dong T, Chen Y, Xu Y, Yang X, Liu P. Ultrasound-targeted microbubble destruction-mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function. Exp Ther Med. 2018;15:31-38. [PMID: 29387180 DOI: 10.3892/etm.2017.5421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018;8:10434. [PMID: 29992975 DOI: 10.1038/s41598-018-28650-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
34 Li S, Ma W, Fei T, Lou Q, Zhang Y, Cui X, Qin X, Zhang J, Liu G, Dong Z, Ma Y, Song Z, Hu Y. Upregulation of heat shock factor 1 transcription activity is associated with hepatocellular carcinoma progression. Mol Med Rep 2014;10:2313-21. [PMID: 25199534 DOI: 10.3892/mmr.2014.2547] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
35 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 121] [Article Influence: 27.2] [Reference Citation Analysis]
36 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
37 Hsu C, Chen BB, Chen CH, Ho MC, Cheng JC, Kokudo N, Murakami T, Yeo W, Seong J, Jia JD. Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2015;4:96-105. [PMID: 26020032 DOI: 10.1159/000367732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
38 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
39 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 569] [Article Influence: 165.3] [Reference Citation Analysis]
40 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
41 Wang WD, Zhang LH, Ni JY, Jiang XY, Chen D, Chen YT, Sun HL, Luo JH, Xu LF. Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis. Korean J Radiol 2018;19:613-22. [PMID: 29962868 DOI: 10.3348/kjr.2018.19.4.613] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
42 Tseng CL, Lai WJ, Huang CJ, Huang YH, Su CW, Lee IC, Tseng HS, Li CP, Lee RC, Lin HC, Chao Y. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. Medicine (Baltimore) 2015;94:e1659. [PMID: 26632677 DOI: 10.1097/MD.0000000000001659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Lin ZY, Wang JH, Yeh ML, Huang CI, Kee KM, Yen YH, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. Kaohsiung J Med Sci 2020;36:750-6. [PMID: 32349190 DOI: 10.1002/kjm2.12221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Chan SL. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;36:74-5. [DOI: 10.1111/j.1365-2036.2012.05125.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Liu PH, Hsia CY, Lee YH, Hsu CY, Huang YH, Su CW, Lee RC, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol. 2015;111:404-409. [PMID: 25643842 DOI: 10.1002/jso.23854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
47 Chong CCN, Lee KF, Chu CM, Chan AWH, Wong J, Chan SL, Lok HT, Fung AKY, Fong AKW, Cheung YS, Yu SCH, Johnson P, Lai PBS. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. HPB (Oxford). 2018;20:546-554. [PMID: 29352659 DOI: 10.1016/j.hpb.2017.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
48 Hashikin NAA, Yeong C, Guatelli S, Abdullah BJJ, Ng K, Malaroda A, Rosenfeld A, Perkins AC. Systematic investigation on the validity of partition model dosimetry for 90 Y radioembolization using Monte Carlo simulation. Phys Med Biol 2017;62:7342-56. [DOI: 10.1088/1361-6560/aa7e5b] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: An Asian perspective: Editorial. Asia-Pacific Journal of Clinical Oncology 2012;8:111-4. [DOI: 10.1111/j.1743-7563.2012.01551.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Hsu CY, Liu PH, Ho SY, Hsia CY, Kudaravalli P, Lee YH, Chiou YY, Tsai YJ, Huang YH, Huo TI. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289. [PMID: 29540157 DOI: 10.1186/s12885-018-4202-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
51 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
52 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
53 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017;23:2545-55. [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
54 Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012;18:6398-408. [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
55 Han DH, Choi GH, Kim KS, Choi JS, Park YN, Kim SU, Park JY, Ahn SH, Han KH. Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. J Gastroenterol Hepatol. 2013;28:1384-1390. [PMID: 23517197 DOI: 10.1111/jgh.12200] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
56 Chan Y, Kabiling CS, Pillai VG, Aguilar G, Wang C, Chen C. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. World J Surg 2015;39:1510-8. [DOI: 10.1007/s00268-015-2975-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
57 Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12:10. [PMID: 25421283 DOI: 10.1038/nrclinonc.2014.122-c1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
58 Yao X, Yan D, Zeng H, Liu D, Li H. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. J Surg Oncol 2016;113:672-7. [PMID: 26989044 DOI: 10.1002/jso.24215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
59 Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H. An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 2015;46:944-952. [PMID: 25524574 DOI: 10.3892/ijo.2014.2798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kim SW, Oh D, Park HC, Lim DH, Shin SW, Cho SK, Gwak GY, Choi MS, Paik YH, Paik SW. Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat Oncol J 2014;32:14-22. [PMID: 24724047 DOI: 10.3857/roj.2014.32.1.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
61 Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016;22:3632-43. [PMID: 27053855 DOI: 10.3748/wjg.v22.i13.3632] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Xiong J, He D, Hu W, Liu X. Retroperitoneal and intrahepatic metastasis from primary clear cell carcinoma of the liver: A case report and review of the literature. Medicine (Baltimore) 2017;96:e6452. [PMID: 28328858 DOI: 10.1097/MD.0000000000006452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Su T, Liang P, Liang J, Lu H, Jiang H, Cheng T, Huang Y, Tang Y, Deng X. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2017;98:639-46. [DOI: 10.1016/j.ijrobp.2017.02.095] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
64 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process. Journal of Hepatology 2015;62:855-62. [DOI: 10.1016/j.jhep.2014.11.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 13.5] [Reference Citation Analysis]
66 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 149] [Article Influence: 33.4] [Reference Citation Analysis]
67 Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, Lee AS, Law A, Zhang JY, Hu Y. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017;6:264-274. [PMID: 29234630 DOI: 10.1159/000475768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
68 Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014;9:e102686. [PMID: 25083860 DOI: 10.1371/journal.pone.0102686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
69 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
70 Ren B, Liu H, Gao H, Liu S, Zhang Z, Fribley AM, Callaghan MU, Xu Z, Zeng Q, Li Y. Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR. Oncotarget 2017;8:93039-50. [PMID: 29190976 DOI: 10.18632/oncotarget.21750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]